论文信息 - NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton's Tyrosine Kinase-Targeted Protein Degrader, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies - 字舞流文

NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton's Tyrosine Kinase-Targeted Protein Degrader, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies

I. Flinn | O. Abdel-Wahab | A. Wiestner | S. O'brien | S. Y. Kim | W. Wierda | T. Siddiqi | A. Mato | W. Ai | M. Tees | A. Danilov | Clare Sun | L. Roeker | D. Bond | M. Patel | K. Patel | Michael L. Wang | M. Tan | E. Meredith | Amanda Schwab | Melissa A. Gessner